4//SEC Filing
NPS PHARMACEUTICALS INC 4
Accession 0001104659-14-087782
CIK 0000890465operating
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 10:15 AM ET
Size
9.2 KB
Accession
0001104659-14-087782
Insider Transaction Report
Form 4
Selisker Rachel R
Director
Transactions
- Exercise/Conversion
Common Stock
2014-12-17$4.24/sh+1,208$5,122→ 11,108 total - Sale
Common Stock
2014-12-17$34.59/sh−3,708$128,260→ 7,400 total - Exercise/Conversion
Stock Options (right to buy)
2014-12-17−1,208→ 0 totalExercise: $4.24Exp: 2019-09-23→ Common Stock (1,208 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.51 to $35.00, inclusive. The reporting person undertakes to provide to NPS Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4.
- [F3]On September 23, 2009, the reporting person received a grant of 36,000 stock options under the Issuer's 2005 Omnibus Incentive Plan. These options vested and became exercisable based on the following vesting schedule: 25% on each of the first anniversary of the date of grant and 6.25% every three months thereafter.. As of the date of this filing, all 36,000 stock options have vested.
Documents
Issuer
NPS PHARMACEUTICALS INC
CIK 0000890465
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0000890465
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 10:15 AM ET
- Size
- 9.2 KB